Azimilide dihydrochloride: A new class III anti-arrhythmic agent

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2705-2715

  Abrol, R ^a   Page, R L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atrial arrhythmia; Atrial fibrillation; Azimilide; Class III anti arrhythmic drug; Pharmacology; Stedicor(TM)

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BENZALDEHYDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLIC ACID; CYTOCHROME P450 3A4; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; ENCAINIDE; FLECAINIDE; IBUTILIDE; KETOCONAZOLE; LIDOCAINE; MEXILETINE; PHENACETIN O DEETHYLASE; PHENYTOIN; PLACEBO; POTASSIUM; POTASSIUM CHANNEL; PROPAFENONE; QUINIDINE; SODIUM; SOTALOL; TOCAINIDE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CALCIUM CURRENT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; EYE TOXICITY; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; POTASSIUM CONDUCTANCE; POTASSIUM CURRENT; PROGNOSIS; SKIN DISCOLORATION; SLOW INWARD CURRENT; SODIUM CURRENT; THYROID DISEASE; TORSADE DES POINTES;

EID: 0033757958     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2705     Document Type: Article

References (53)

1. Management of patients with atrial fibrillation: A statement for healthcare professionals from the committee on electrocardiography and electrophysiology, AHA
2. Atrial fibrillation: A review of mechanism, etiology and therapy
3. Atrial fibrillation begets atrial fibrillation
4. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility
5. Anti-arrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization
6. Atrial Fibrillation Following Investigation of Rhythm Management: AFFIRM study design
7. Atrial fibrillation: From cell to bedside
8. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia
9. Anti-arrhythmic drug therapy and cardiac mortality in atrial fibrillation
10. What should we expect from the next generation of anti-arrhythmic drugs?
11. Anti-arrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm
12. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials
13. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
14. Effect of the anti-arrhythmic agent moricizine on survival after myocardial infarction
15. Pharmacological and pharmacokinetic profile of class III anti-arrhythmic drugs
16. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation
17. Controlled trial of sotalol for one year after myocardial infarction
18. A comparison of seven antiarrhythmic drugs in patients with ventricular tacharrhythmias. Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Investigators
19. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral D-Sotalol
20. Cellular electrophysiology of amiodarone
21. Low dose amiodarone for atrial fibrillation
22. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators
23. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
24. Evidence-based analysis of amiodarone efficacy and safety
25. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
26. + currents in human atrial and ventricular myocytes
27. Use-dependent effects of the class III anti-arrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents
28. The azimilide post-infarct survival evaluation (ALIVE) trial
29. Introduction. A symposium: Can anti-arrhythmic drugs survive survival trials?
30. Blockade of HERG channels by the class III antiarrhythmic azimilide: Mode of action
31. Azimilide causes reverse rate-dependent block while reducing both components of delayed-rectifier current in canine ventricular myocytes
32. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: Dependence on blockade of K, Ca and Na channels
33. Azimilide dihydrochloride, a novel anti-arrhythmic agent
34. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia
35. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model
36. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs
37. The class III anti-arrhythmic NE-10064 increase QTc interval with minor hemodynamic effects in anesthetized dogs
38. Effects of intravenously administered NE-10064 [azimilide] on programmed electrical stimulated (PES)-induced ventricular arrhythmias in anaesthetised dogs
39. Effects of the novel anti-arrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties
40. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride
41. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction
42. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride
43. Azimilide treatment of atrial fibrillation
44. Dose response of azimilide for prevention of atrial fibrillation or flutter
45. Dose response for azimilide treatment of paroxysmal supraventricular tachycardia
46. Antiarrhythmic effects of azimilide in atrial fibrillation
47. Safety aspects of azimilide in patients with an implantable cardioverter defibrillator: 1 year follow-up
48. Effects of Azimilide, an Ikr and Iks Potassium Channel Blocker in Patients With Implantable Cardioverter Defibrillator
49. Azimilide reduces the frequency of shocks in patients with an implantable cardioverter-defibrillator programmed for pacing and shock: Andersen-Gill model
50. Survival of patients treated with azimilide for atrial fibrillation and other supraventricular arrhythmias